Precision Neuroscience is pressing its case that brain-computer technology has moved beyond theory and into the hard realities of product development.

Speaking at the Milken Institute Global Conference in Beverly Hills, California, co-founder and CEO Michael Mager discussed the company’s work on a neurological implant built to create a communication link between the brain and external computers. The conversation also put fresh attention on Precision’s partnership with Medtronic, a major signal that the company wants to pair ambitious science with the manufacturing and commercial muscle needed to reach patients.

The central promise is simple to describe and hard to deliver: build a reliable bridge between neural activity and the digital tools outside the body.

That challenge sits at the center of a crowded and closely watched field. Companies developing brain-computer interfaces must prove that their devices can work safely, capture useful signals, and fit into a medical system that demands years of testing and validation. Precision’s message, as outlined in the interview, suggests the company sees partnership as a way to speed that path rather than try to build every piece alone.

Key Facts

  • Precision Neuroscience is developing a neurological implant that links the brain with external computers.
  • CEO Michael Mager discussed the effort at the Milken Institute Global Conference in Beverly Hills.
  • The company’s partnership with Medtronic stands out as a key part of its strategy.
  • Reports indicate the focus remains on turning brain-computer interface research into practical medical technology.

The Medtronic connection matters because it hints at how this sector may evolve: not just through headline-grabbing prototypes, but through alliances that tackle engineering, regulatory work, and eventual scale. Sources suggest investors and industry observers will watch closely for any sign of how responsibilities split between the two companies and how quickly the collaboration can translate into concrete milestones.

What comes next will determine whether Precision Neuroscience can separate itself in a field full of bold promises. The company now faces the harder phase: showing measurable progress, navigating oversight, and proving that a brain-linked device can deliver real-world value. If it succeeds, the implications will stretch far beyond one company’s balance sheet and into the future of how people interact with machines.